Twist Bioscience vs Beam Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.
About
Twist Bioscience was founded in 2013 in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, pioneering a silicon-based DNA synthesis platform that writes synthetic DNA at a fraction of the cost and error rate of conventional methods. By printing DNA on silicon wafers using a semiconductor-like process, Twist dramatically reduced the cost of synthetic genes from hundreds to single-digit dollars per gene, democratizing access to DNA writing for the life sciences.\n\nTwist serves over 3,000 customers across biopharmaceuticals, academic research, agriculture, and industrial biotechnology, offering synthetic genes, variant libraries, DNA data storage oligos, and antibody libraries for drug discovery. The company reported $376.6 million in FY2025 revenue, up 20% from $313 million in FY2024, driven by strong growth in its biopharma and drug discovery segments. Twist also operates a growing antibody drug discovery business, providing synthetic antibody libraries that power next-generation therapeutic discovery programs.\n\nTwist has a supply agreement with Ginkgo Bioworks for synthetic DNA to fuel Ginkgo's cell engineering platform, revised in 2025. The company is executing toward profitability, with improving gross margins as manufacturing scale increases. Its silicon-based DNA synthesis platform positions it as critical infrastructure for the emerging bioeconomy, synthetic biology, and DNA data storage industries.
Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.
About
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.